Search

Your search keyword '"Holgado, Esther"' showing total 16 results

Search Constraints

Start Over You searched for: Author "Holgado, Esther" Remove constraint Author: "Holgado, Esther" Journal journal of clinical oncology Remove constraint Journal: journal of clinical oncology
16 results on '"Holgado, Esther"'

Search Results

1. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

2. Evolution of the myeloid-derived suppressor cells in advanced breast cancer and comparative analysis with a healthy population cohort.

3. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

4. Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.

5. Tumor infiltrating lymphocytes before and after dual HER2 blockade in HER2-amplified early breast cancer: A TRYPHAENA substudy.

6. Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets).

7. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

8. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).

9. A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM), pemetrexed (PEM) & carboplatin (CARBO) in pts with 1st line non-squamous NSCLC.

11. Lurbinectedin (PM01183) with doxorubicin (DOX), an active treatment as second-line therapy in small cell lung cancer (SCLC).

12. GBM cell microvesicles carrying gDNA oncogenic sequences cross the BBB and reach the peripheral blood.

13. High level of suppressor-of-fused (SuFu) expression and tumor cells dissemination in human glioblastoma.

Catalog

Books, media, physical & digital resources